![]() |
|
|
|||||||
|
|
LinkBack | Thread Tools | Display Modes |
|
|||
|
Privately held Ablitech last week announced that it has received a $2 million grant from the US Department of Defense to develop its siRNA delivery technology for the treatment of heterotopic ossification, a condition characterized by painful bone growths following injuries and trauma.
|
| Thread Tools | |
| Display Modes | |
|
|